Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 7/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.46 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318870 | 1.00 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL2517387 | 1.00 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL1174387 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL836565 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL19559844 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL4677717 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL8330499 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL2715188 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL10296149 | 0.79 | SLC7A5 (0.54) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL13789959 | 0.79 | SLC7A5 (0.54) | SLC7A5LARS1ANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | claimed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | claimed |
| WO-2010065709-A2 | HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | KHAN AMIN (US) | 2010-06-10 | — | — | WO | claimed |
| CN-1702168-A | L-leucine high-yield bacterium and fermentation method using the same for L-leucine production | WUXI JINGHAI AMINO ACID CO LTD (CN) | 2005-11-30 | — | — | CN | claimed |
| US-11866737-B2 | 2-isopropylmalate synthetase and engineering bacteria and application thereof | TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-01-09 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210189354-A1 | 2-ISOPROPYLMALATE SYNTHETASE AND ENGINEERING BACTERIA AND APPLICATION THEREOF | TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-06-24 | — | — | US | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| CN-1314798-C | L-leucine high-yield bacterium and fermentation method using the same for L-leucine production | WUXI JINGHAI AMINO ACID CO LTD (CN) | 2007-05-09 | — | — | CN | disclosed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | disclosed |
| CN-1702168-A | L-leucine high-yield bacterium and fermentation method using the same for L-leucine production | WUXI JINGHAI AMINO ACID CO LTD (CN) | 2005-11-30 | — | — | CN | disclosed |
| CN-1215055-C | Arylsulfonylamino-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | SLC7A5 337/4885LARS1 1284/4885ANPEP 434/4885 |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | SLC7A5 337/4885LARS1 1284/4885ANPEP 434/4885 |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | MMP13, MMP2, MMP1 | SLC7A5 128/4885LARS1 3556/4885ANPEP 210/4885 |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | SLC7A5 1577/4885LARS1 3105/4885ANPEP 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.